Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019656 · ClinicalTrials.gov registry record · Phase 1
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
NCT00019656 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by National Cancer Institute (NCI). The trial reports 2 study locations across 1 state.
The verdict
NCT00019656, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory solid tumors or hematologic cancer.
Conditions Studied
Interventions
- DRUG perifosine
Study Locations (2)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
- NCI - Center for Cancer Research - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019656
The ClinicalTrials.gov registry entry for NCT00019656 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which perifosine is the first listed.
NCT00019656 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00019656 about?
NCT00019656 is a clinical study titled "Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory solid tumors or hematologic cancer.
What is the current status of trial NCT00019656?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-08.
What conditions does trial NCT00019656 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Myelodysplastic/Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT00019656?
The interventions under investigation include: perifosine (DRUG).
Who is sponsoring clinical trial NCT00019656?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00019656 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.